We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.88 | -0.68% | 127.92 | 129.76 | 127.985 | 129.76 | 7,446,078 | 01:00:00 |
From May 2023 to May 2024
By Colin Kellaher
Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its antiviral agent Prevymis against a common viral infection experienced by transplant recipients.
The Kenilworth, N.J., drugmaker said the approval covers Prevymis for the prevention of cytomegalovirus disease in adult kidney transplant recipients at high risk.
Prevymis, which the FDA first approved in 2017, generated revenue of $428 million last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 06, 2023 07:32 ET (11:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
